Cyclosporine-induced detachment of vascular endothelial cells initiates the intrinsic coagulation system in plasma and whole blood

Journal of Laboratory and Clinical Medicine

Volumn 127, Issue 6, 1996, Pages 621-634

  Bombeli, Thomas ^a,b   Müller, Michele ^a   Straub, P Werner ^a   Haeberli, André ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0030174289     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(96)90153-5     Document Type: Article

References (52)

1. Kahan BD. Cyclosporine. N Engl J Med 1989;321:1725-38.
2. Klintmalm GBG, Iwatsuki S, Starzl TE. Nephrotoxicity of cyclosporin A in liver and kidney transplant recipients. Lancet 1981;1:470-1.
3. Atkinson K, Biggs JC, Hayes J, et al. Cyclosporin A associated nephrotoxicity in the first 100 days after allogeneic bone marrow transplantation: three distinct syndromes. Br J Haematol 1983;54:59-67.
4. Feutren G, Mihatsch M. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. N Engl J Med 1992;326:654-60.
5. Abraham JS, Bentley FR, Garrison RN. The role of intrarenal prostaglandins and angiotensin II in acute cyclosporine-induced vasoconstriction. Surgery 1991;110:343-9.
6. Mehring N, Neumann KH, Rahn KH, Zidek W. Mechanisms of cyclosporin A-induced vasoconstriction in the isolated perfused rat kidney. Nephron 1992;60:477-81.
7. Mihatsch MJ, Thiel G, Ryffel B. Histopathology of cyclosporine nephrotoxicity. Transplant Proc 1988;20(suppl 3):759-71.
8. Mihatsch MJ, Thiel G, Spichtin HP, et al. Morphological findings in kidney transplants after treatment with cyclosporine. Transplant Proc 1983;15:2821-6.
9. Cohen H, Bull A, Seddon A, et al. Vascular endothelial cell function and ultrastructure in thrombotic microangiopathy following allogeneic bone marrow transplantation. Eur J Haematol 1989;43:207-14.
10. Guillemain R, Farge D, Amrein C, et al. Thrombotic microangiopathy with reversible acute renal failure in a cardiac transplant recipient under cyclosporin. Clin Nephrol 1990;34: 237-8.
11. Bonser RS, Adu D, Franklin I, McMaster P. Cyclosporin-induced haemolytic uraemic syndrome in liver allograft recipient [Letter]. Lancet 1984;2:1337.
12. Van Buren D, Van Buren CT, Flechner SM, et al. De novo hemolytic uremic syndrome in renal transplant patients immunosuppressed with cyclosporine. Surgery 1985;98:54-62.
13. Vanrenterghem Y, Roels L, Lerut T, et al. Thromboembolic complications and haemostatic changes in cyclosporin-treated cadaveric kidney allograft recipients. Lancet 1985;1: 999-1002.
14. Bergentz SE, Bergqvist D, Bornmyr S, Brunkwall J, Husberg B. Venous thrombosis and cyclosporin. Lancet 1985;2:101-4.
15. Lafoz E, Monreal M, Casals A, Garcia-Teresa G. Cyclosporin and deep venous thrombosis [Letter]. Med Clin 1990;95: 117.
16. Seeber C, Hiller E, Holler E, Kolb HJ. Increased levels of tissue plasminogen activator (t-PA) and tissue plasminogen activator inhibitor (PAI) correlate with tumor necrosis factor alpha (TNF-α)-release in patients suffering from micorangiopathy following allogenic bone marrow transplantation (BMT). Thromb Res 1992;66:373-83.
17. Evans SM, Giddings JC, Whittaker JA, et al. Prothrombotic effects of cyclosporin A, in vitro and in vivo [Abstract]. Thromb Haemost 1995;73:908.
18. Voss BL, Hamilton KK, Samara EN, et al. Cyclosporine suppression of endothelial prostacyclin generation: a possible mechanism for nephrotoxicity. Transplantation 1988;45:793-6.
19. Brown Z, Neild GH. Cyclosporine inhibits prostacyclin production by cultured human endothelial cells. Transplant Proc 1987;19:1178-80.
20. Brown Z, Neild GH, Lewis GP. Inhibition of prostacyclin formation by cyclosporin is not due to reduced availability of arachidonic acid in membrane phospholipids of cultured human endothelial cells. Biochem Pharmacol 1990; 39:1136-8.
21. 2 formation by rat mesangial cells in culture. Kidney Int 1989;35:1161-7.
22. 2 formation in isolated glomeruli and papilla of rat kidneys. Clin Nephrol 1986;25(suppl 1):S78-82.
23. Kurtz A, Pfeilschifter J, Kühn K, Koch KM. Cyclosporin A inhibits PGE2 release from vascular smooth muscle cells. Biochem Biophys Res Commun 1987;147:542-9.
24. Grace AA, Barradas MA, Mikhailidis DP, et al. Cyclosporine A enhances platelet aggregation. Kidney Int 1987;32:889-95.
25. 2 synthesis induced by cyclosporin A. Am J Physiol 1986;251: 581-7.
26. Coffmann TM, Carr DR, Yarger WE, Klotman PE. Evidence that renal prostaglandin and thromboxane production is stimulated in chronic cyclosporine nephrotoxicity. Transplantation 1987;43:282-5.
27. Cohen H, Neild GH, Patel R, Mackie IJ, Machin SJ. Evidence for chronic platelet hyperaggregability and in vivo activation in cyclosporin-treated renal allograft recipients. Thromb Res 1988;49:91-101.
28. Frampton G, Parbtani A, Marchesi D, et al. In vivo platelet activation and in vitro hyperaggregability to arachidonic acid in renal allograft recipients. Kidney Int 1983;23:506-13.
29. Carlsen E, Mallet AC, Prydz H. Effect of cyclosporine A on procoagulant activity in mononuclear blood cells and monocytes in vitro. Clin Exp Immunol 1985;60:407-16.
30. Carlsen E, Prydz H. Enhancement of procoagulant activity in stimulated mononuclear blood cells and monocytes by cyclosporine. Transplantation 1987;43:543-8.
31. Ryan J, Geczy CL. Charaterization and purification of mouse macrophage procoagulant-inducing factor. J Immunol 1986; 137:2864-70.
32. 2 on the allogeneic induction on monocyte/macrophage procoagulant activity and the cytokine macrophage procoagulant-inducing factor and interleukin-2. Immunology 1991;74:670-6.
33. Brown Z, Neild GH, Willoughby JJ, Nikunji VS, Cameron SJ. Increased factor VIII as an index of vascular injury in cyclosporine nephrotoxicity. Transplantation 1986;42:150-3.
34. Charba D, Moake JL, Harris MA, Hester JP. Abnormalities of von Willebrand factor multimers in drug-associated thrombotic microangiopathies. Am J Hematol 1993;42:268-77.
35. Pfliegler G, Boda Z, Harsfalvi J, et al. Successful cyclosporin therapy of acquired hemophilia caused by factor VIII (VIII:C) inhibiting antibody. Orv Hetil 1991;132:1485-8.
36. Yoshida M, Kozaki M, Ioya N, et al. Plasma thrombomodulin levels as an indicator of vascular injury caused by cyclosporine nephrotoxicity. Transplantation 1990;50:1066-9.
37. Zoja C, Furci L, Ghilardi F, Qilio P, Benigni A, Remuzzi G. Cyclosporine-induced endothelial cell injury. Lab Invest 1986;55:455-9.
38. Nitta K, Uchida K, Tsutsui T, et al. Cyclosporin A induces glomerular endothelial cell injury in vitro. Acta Pathol Jpn 1993;43:367-71.
39. Bunchman TE, Brookshire CA. Cyclosporine inhibition of adherence proteins and factor VIII of vascular endothelium. Transplant Proc 1991;23:332-3.
40. Jaffe EA, Nachmann RL, Becker CG, Minich CR. Culture of human endothelial cells derived from umbilical veins. J Clin Invest 1973;52:2745-56.
41. Burgess WH, Mehlman T, Friesel R, Johnson WV, Maciag T. Multiple forms of endothelial cell growth factor. J Biol Chem 1985;260:11389-92.
42. Biedermann B, Rosenmund A, Müller M, Kohler HP, Haeberli A, Straub PW. Human endothelial cells suppress prothrombin activation in non-anticoagulated whole blood in vitro. J Lab Clin Med 1994;124:339-47.
43. Kohler HP, Müller M, Bombeli T, Straub PW, Haeberli A. The suppression of the coagulation of non-anticoagulated whole blood in vitro by human umbilical vein endothelial cells cultivated on microcarriers is not dependent on protein C activation. Thromb Haemostas 1995;73:719-24.
44. Kohler HP, Müller M, Haeberli A, Straub PW. Human umbilical vein endothelial cells on microcarriers suppress thrombin generation in recalcified human citrated plasma in vitro [Abstract]. Thromb Haemost 1993;69:1250.
45. Moldow CF, Bach RR, Staskus K, Rick PD. Induction of endothelial tissue factor by endotoxin and its precursors. Thromb Haemost 1993;70:702-6.
46. Carlsen E, Flatmark A, Prydz H. Cytokine-induced procoagulant activity in monocytes and endothelial cells. Further enhancement by cyclosporine. Transplantation 1988;46:575-80.
47. Rodgers GM, Greenberg CS, Shuman MA. Characterization of the effects of cultured vascular endothelial cells on the activation of blood coagulation. Blood 1983;61:1155-62.
48. Colman RW, Walsh PN. Mechansims of platelet aggregation. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and thrombosis: basic principles and clinical practice. Philadelphia: Lippincott, 1987:594-605.
49. Mulder AB, Hegge-Paping KSM, Magielse CPE, et al. Tumor necrosis factor-induced endothelial tissue factor is located on the cell surface rather than in the subendothelial matrix. Blood 1994;84:1559-66.
50. Moore K, Andreoli SP, Esmon NL. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest 1987;79: 124-30.
51. Garcia-Maldonado M, Kaufman CE, Comp PC. Decrease in endothelial cell-dependent protein C activation induced by thrombomodulin by treatment with cyclosporine. Transplantation 1991;51:701-5.
52. Busso N, Huet S, Nicodeme E, Hiernaux J, Hyafil F. Refractory period phenomenon in the induction of tissue factor expression on endothelial cells. Blood 1991;78:2027-35.